Financial Outlook
for 2025
Looking ahead to 2025, we anticipate continued growth of our medical dermatology portfolio, driven by our strong presence and commercial execution in Europe. With rising demand for advanced treatments like biologics and the strong position of our products, we project our biological portfolio to reach peak sales of more than €800 million by 2030.
Go back to Growing the business & Innovating
Our commitment to innovation and collaboration is reinforced through strategic partnerships with companies such as Eli Lilly, Sun Pharma, and others. For example, our partnership with Sun Pharma includes a range of additional clinical studies of tildrakizumab. By advancing comprehensive programmes of clinical trials and fostering key partnerships, we will continue to push boundaries in dermatology by developing ground-breaking treatments.
In line with our expansion strategy, we will further progress the rollout of Ebglyss® (lebrikizumab), extending its presence to the remaining key countries in Europe.
we expect sustained growth momentum across our dermatology portfolio in Europe
Ilumetri®
(tildrakizumab)
Bolstered by achieving
26% YoY in 2024 and the launch
of a 200 mg dose alternative
Wynzora®
Klisyri®
Key contributors to the overall growth of the dermatology portfolio.
Our R&D pipeline will play a crucial role in achieving long-term success, with anticipated progress in several early-stage projects aimed at advancing novel treatment options through our deep scientific understanding of skin diseases.
With a strategic focus on M&A operations that add value to our portfolio and strengthen key partnerships, we remain committed to sustainable growth, balancing impactful innovation with a sustained and long-term financial approach.
2025
GUIDANCE
€220 MM - €240 MM
10% - 13%
with total ebitda
we expect net sales to grow
For the full financial statements, please visit: www.almirall.com/investors
